88%Confidence
0Views
FDASource
2026-03-14Date
Summary
Wizcure's Vista Meibo Tears recall completes a pattern of sterility failures across its eye care range, severely compromising hi-health's product offerings. This suggests hi-health may need to find new manufacturing partners to restore market credibility.
Actionable: Conduct a full audit of all hi-health products manufactured by Wizcure and initiate a supplier qualification process for replacements.
AI Confidence: 88%
Data Points
firmWizcure Pharmaa Private Limited
classificationClass II
statusOngoing
distributionDistributed Nationwide in the USA
productVista Meibo Tears Propylene Glycol 0.6% w/v Eye Drops Advanced Dry Eye Relief Revitalizing Formula, 10 ml (1/3 fl.oz.), Wizcure Pharmaa PVT. LTD., H-8
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now